Table 1 Characteristics of subjects entered into the Astra Zeneca sponsored clinical study D1330N00013 whose blood samples where utilised in the present study
Patient | Age (Median) | Performance status (Who) | Stage | Grade (Gleason) | Baseline PSA (Median, ng/ml) |
|---|---|---|---|---|---|
Group I | 71 | Normal-Restricted Activity | Localised | Intermediate (5–7) | 7.0 |
Group II | 74 | Normal-Restricted Activity | Locally Advanced/ Metastatic | High (8–10) | 23.2 |